Florida Cancer Specialists & Research Institute | Strategic Alliance Partners

About Florida Cancer Specialists & Research Institute, LLC: (Homepage)

Florida Cancer Specialists & Research Institute (FCS) offers patients access to more clinical trials than any private oncology practice in Florida. The majority of new cancer drugs recently approved for use in the U.S. were studied in clinical trials with FCS participation.* Recognized for our research, FCS is a recipient of the national Clinical Trials Participation Award presented by the American Society of Clinical Oncology (ASCO). FCS physicians, trained in prestigious medical schools and research institutes, are consistently ranked nationally as Top Doctors by U.S. News & World Report.

Celebrating its 40th year in 2024, FCS has built a national reputation for excellence that is reflected in exceptional and compassionate patient care, driven by innovative clinical research, cutting-edge technologies and advanced treatments, including targeted therapies genomic-based treatment and immunotherapy. Our highest values are embodied by our outstanding team of highly trained and dedicated physicians, clinicians and staff.

Connect with us:

Latest from Florida Cancer Specialists & Research Institute

CMS Claims Data Provide Glimpse of True Cost Picture

October 27, 2017

Article

As the Oncology Care Model practices work to reduce Medicare’s overall spending on those patients and to earn shared savings payments, the data are providing them with an unprecedented full picture of the extent and cost of care.

Novel Strategies Recommended for Oral Adherence

May 01, 2017

Article

With the increase of oral medications in oncology, adherence has become a significant issue since patients take the drugs home with them, and whether or not they stick to a regimen is hidden from the provider's view.

Consolidation Ripples Out From Florida

December 29, 2016

Article

Florida is a leader in the consolidation trend, topping the nation in the number of practices that have closed, merged, or been acquired in recent years.

Expert Highlights Ongoing Progress in ALK+ NSCLC

December 21, 2016

Article

Frontline therapy for patients with ALK-positive non–small cell lung cancer is poised to change in the coming years, as researchers continue to explore agents beyond crizotinib.

Dr. Hart on Advances in ALK+ NSCLC

December 01, 2016

Video

Lowell L. Hart, MD, scientific director of Research at Florida Cancer Specialists & Research Institute, and associate professor of Internal Medicine at Wake Forest School of Medicine, discusses the recent advances in the area of ALK-positive non–small cell lung cancer.

Florida Practices Band Together for Strength

June 09, 2016

Article

Florida Cancer Specialists & Research Institute has honed its merger strategy into a finely tuned regimen that goes from due diligence to planning to implementation and follow-up, all in a period as short as 120 days.

In-House Pharma Feeling the Pressure From Drug Industry Competition

February 10, 2016

Article

Newer, more stringent USP 800 regulations on cleanrooms are a couple of years off, thanks to a postponement of implementation, but they're still a worry for independent oncology practices, whose in-house pharmacy staff may sit up nights wondering about the stability of their drug revenues.

Florida Doctors Trade Independence for Security in Epicenter of Merger Wave

June 04, 2015

Article

The array of services and opportunities with which Florida Cancer Specialists & Research Institute provides its physicians, while still allowing them a high degree of autonomy, has proved a powerful draw since the group was founded as a solo practice by William Harwin, MD, in 1984.

How One Oncology Practice Took Advantage of Economies of Scale

November 12, 2013

Article

One oncology practice in Florida seems to have been able to adapt its practice model, taking advantage of economies of scale, and identifying new revenue streams, while still providing quality care and keeping its oncologists satisfied professionally.